Biofrontera stock (BFRI) rallies 115%, fired up by upbeat rating

Be the First to Comment Read

Biofrontera stock (BFRI) rallies 115%, fired up by upbeat rating

Follow us on Google News:
 Biofrontera stock (BFRI) rallies 115%, fired up by upbeat rating
Image source: Billion Photos,Shutterstock


  • Analysts raised the 12-month stock price target to US$20.

  • The BFRI jumped 115% in intraday trading after the positive comments.

  • The Massachusetts-based company specializes in dermatology drugs and medical cosmetics, mainly for skin diseases caused by sunburn.

Shares of Biofrontera Inc. (NASDAQ: BFRI) jumped more than 115% after positive analysts rating for the stock. It was trading at US$5.68 at 11:31 am ET, up 115.97% from its last close.

After considering Biofrontera’s revenue potential from the drugs Amelux and Xepi, Wall Street analysts projected a 12-month stock price target of US$20 for the stock. These two approved drugs are seen as fundamental to Biofrontera’s growth over the next few months.

The Biofrontera stock declined about 40% this year. But these two drugs offer a silver lining - an opportunity to improve its declining stock prices. Analysts expect improved US sales for Amelux and Xepi. The upbeat assessment drove up the stock price in intraday trading on Wednesday.

Also Read: Ocuphire Pharma (OCUP) stock jumped 34% - know why?

The Woburn, Massachusetts-based biopharmaceutical company specializes in dermatological drugs and medical cosmetics, especially for skin diseases caused by sunburn.

The company was established by Hermann Lubbert in 1997.

Lubbert leads the company as its CEO.

Biofrontera’s lead product is a combination of Ameluz, a topical prescription drug, and BF-RhodoLED, a medical device. Ameluz is designed to treat patients suffering from superficial skin cancers with "photodynamic therapy.”

Its other important products include Xepi and Belixos.

Also Read: Grocery delivery firm Instacart going public? All you need to know

Shares of Biofrontera Inc (BFRI) rallied after analysts gave upbeat rating for the stock and set a 12-month price target of US$20 per share.

Also Read: Top oil and gas stocks to explore after US taps strategic reserves

Stock performance and financials

The Massachusetts-based firm has a market cap of US$63.45 million. Its stock saw the highest price of US$4.99 and the lowest price of US$2.25 in the last 52 weeks.

Its trading volume on November 23 was 324,366.

Biofrontera will report its third-quarter earnings for fiscal 2021 on November 30 at 4:30 pm ET.

It started trading on Nasdaq on Oct 29, 2021.

For the six months ended on June 30, 2021, its net revenue was US$10.59 million compared to US$7.02 million in the same period a year ago. Its net loss was US$7.19 million against a loss of US$7.81 million for the six months ended on June 30, 2020.

Also Read: Pasithea Therapeutics (KTTA) stock soars 229% - Know why?


The healthcare sector is among the top performers this year, helped by strong demand for covid vaccines and other healthcare support. Robust investments in drug research and development and speedy approvals also facilitated its growth.


Featured Articles